| Status: Partially superseded | |||
AWMSG ADVICE PARTIALLY SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2017. Refer to TA481: Immunosuppressive therapy for kidney transplant in adults for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. Tacrolimus (Envarsus®) is recommended as an option for use within NHS Wales for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients. |
|||
|
|||
Medicine details |
|||
| Medicine name | tacrolimus (Envarsus®) | ||
| Formulation | 0.75 mg, 1 mg and 4 mg prolonged-release tablet | ||
| Reference number | 2586 | ||
| Indication | Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients |
||
| Company | Chiesi Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Limited | ||
| Status | Partially superseded | ||
| Advice number | 2315 | ||
| NMG meeting date | 10/06/2015 | ||
| AWMSG meeting date | 15/07/2015 | ||
| Ratification by Welsh Government | 27/08/2015 | ||
| Date of issue | 02/09/2015 | ||
| Date of last review | 21/05/2019 | ||
| NICE guidance | TA481: Immunosuppressive therapy for kidney transplant in adults |
||